Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.52 |
| ▸ | CCND1 | P24385 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21662998 | 0.89 | CDK4 (0.52) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL21663305 | 0.83 | CDK4 (0.48) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL21663174 | 0.79 | CDK4 (0.35) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL21663167 | 0.71 | CDK4 (0.50) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL34470301 | 0.68 | RORC (0.35) | KDM4EALDH1A1POLB | |
| SCHEMBL21662994 | 0.66 | CDK4 (0.40) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL21663312 | 0.66 | DRD3 (0.34) | KDM4EALDH1A1POLBDRD3CYP2D6 | |
| SCHEMBL21663152 | 0.66 | CDK9 (0.34) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL21663206 | 0.65 | PIK3CD (0.37) | CDK4CCND1KDM4EALDH1A1POLB | |
| SCHEMBL21160813 | 0.64 | IGF1R (0.39) | CDK4CCND1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. | 2021-11-09 | — | — | US | disclosed |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | CYP2D6, PNPO, CYP2B6 | CDK4 973/4885CCND1 2561/4885KDM4E 3449/4885 |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CYP2D6, PNPO, CYP2B6 | CDK4 973/4885CCND1 2561/4885KDM4E 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.